CSIMarket
 


Ovid Therapeutics Inc   (OVID)
Other Ticker:  
 

Ovid Therapeutics Inc 's Leverage Ratio

OVID's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 144.24%, Leverage Ratio fell to 0.63, above the Ovid Therapeutics Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 72 other companies have achieved lower Leverage Ratio than Ovid Therapeutics Inc in the IV Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 518 to 563 .

Explain Leverage Ratio?
Who are OVID Customers?
What are OVID´s Total Liabilities?


OVID Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -33.62 % -28.69 % -27.24 % -26.7 % -26.41 %
Y / Y Total Liabilities Change 144.82 % -24.24 % 166.79 % 111.34 % 51.77 %
Leverage Ratio MRQ 0.63 0.22 0.22 0.18 0.17
OVID's Total Ranking # 563 # 518 # 292 # 429 # 439
Seq. Equity Change -13.32 % -8.5 % -8.47 % -8.56 % -6.88 %
Seq. Total Liabilities Change 144.24 % -8.44 % 13.74 % -3.76 % -24.41 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 162
Overall Market # 563


Leverage Ratio Statistics
High Average Low
0.74 0.2 0.05
(Dec 31 2020)   (Sep 30 2017)




Financial Statements
Ovid Therapeutics Inc 's Equity $ 88 Millions Visit OVID's Balance sheet
Ovid Therapeutics Inc 's Total Liabilities $ 55 Millions Visit OVID's Balance sheet
Source of OVID's Sales Visit OVID's Sales by Geography


Cumulative Ovid Therapeutics Inc 's Leverage Ratio

OVID's Leverage Ratio for the trailling 12 Months

OVID Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -33.62 % -28.69 % -27.24 % -26.7 % -26.41 %
Y / Y Total Liabilities TTM Growth 144.82 % -24.24 % 166.79 % 111.34 % 51.77 %
Leverage Ratio TTM 0.29 0.2 0.19 0.15 0.12
Total Ranking TTM # 489 # 2 # 2 # 1 # 3
Seq. Equity TTM Growth -13.32 % -8.5 % -8.47 % -8.56 % -6.88 %
Seq. Total Liabilities TTM Growth 144.24 % -8.44 % 13.74 % -3.76 % -24.41 %


On the trailing twelve months basis Due to the net new borrowings of 144.24% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLeverage Ratio improved to 0.29, above the Ovid Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 69, during the past 12 months, other companies have achieved lower Leverage Ratio than Ovid Therapeutics Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 2 to 489.

Explain Leverage Ratio?
Who are OVID Customers?
What are OVID´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 152
Within the Market # 489


trailing twelve months Leverage Ratio Statistics
High Average Low
0.45 0.18 0.07
(Dec 31 2020)   (Dec 31 2021)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Catalent Inc   1.71 $ 6,301.000  Millions$ 3,687.000  Millions
Xoma Corporation  1.64 $ 145.580  Millions$ 88.721  Millions
Summit Therapeutics Inc   1.61 $ 125.257  Millions$ 77.692  Millions
Cumberland Pharmaceuticals Inc  1.59 $ 46.528  Millions$ 29.260  Millions
Merck and Co Inc   1.58 $ 59,431.000  Millions$ 37,635.000  Millions
Pfizer Inc  1.54 $ 137,487.000  Millions$ 89,288.000  Millions
Ocular Therapeutix Inc   1.54 $ 139.916  Millions$ 91.131  Millions
Liquidia Corporation  1.50 $ 71.039  Millions$ 47.293  Millions
Lexicon Pharmaceuticals Inc   1.46 $ 136.319  Millions$ 93.110  Millions
Viatris Inc   1.33 $ 27,218.100  Millions$ 20,467.400  Millions
Lifevantage Corp  1.30 $ 35.375  Millions$ 27.307  Millions
Verastem inc   1.24 $ 71.185  Millions$ 57.374  Millions
2seventy Bio Inc   1.21 $ 310.126  Millions$ 255.300  Millions
Cara Therapeutics inc   1.20 $ 68.759  Millions$ 57.085  Millions
Sonoma Pharmaceuticals Inc   1.18 $ 7.926  Millions$ 6.692  Millions
Perrigo Company Plc  1.18 $ 5,615.400  Millions$ 4,767.900  Millions
Elanco Animal Health Inc  1.16 $ 7,205.000  Millions$ 6,223.000  Millions
Johnson and Johnson  1.16 $ 79,590.000  Millions$ 68,774.000  Millions
Novartis Ag  1.14 $ 53,195.000  Millions$ 46,750.000  Millions
Kiora Pharmaceuticals Inc  1.10 $ 6.716  Millions$ 6.110  Millions
Ani Pharmaceuticals Inc  1.09 $ 471.673  Millions$ 432.749  Millions
Prestige Consumer Healthcare Inc   1.09 $ 1,739.176  Millions$ 1,600.577  Millions
Assertio Holdings inc   1.08 $ 148.416  Millions$ 138.003  Millions
Sonnet Biotherapeutics Holdings Inc   1.07 $ 2.765  Millions$ 2.572  Millions
Eton Pharmaceuticals Inc   1.05 $ 16.263  Millions$ 15.477  Millions
Arvinas Inc   0.98 $ 644.600  Millions$ 660.000  Millions
Royalty Pharma Plc  0.97 $ 9,772.199  Millions$ 10,084.289  Millions
Cryoport inc   0.96 $ 468.721  Millions$ 489.023  Millions
Macrogenics Inc   0.96 $ 145.805  Millions$ 152.613  Millions
Entrada Therapeutics Inc   0.94 $ 226.832  Millions$ 242.360  Millions

Date modified: 2024-03-10T16:12:56+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com